Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Kezar Life Sciences Inc KZR

Healthcare Biotechnology
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and... see more

Current News (NDAQ:KZR)

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis

Business Wire 10 days ago

Kezar Life Sciences Reports Third Quarter 2025 Financial Results

Business Wire November 12, 2025

Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2025

Business Wire November 7, 2025

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

Business Wire October 16, 2025

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

Business Wire August 28, 2025

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Business Wire August 13, 2025

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

Business Wire July 15, 2025

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

Business Wire May 28, 2025

Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

Business Wire May 13, 2025
View More News ››

Opinion & Analysis (NDAQ:KZR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:KZR)

Using technical analysis for this stock.

It is starting a big uptrend for shareholders today,so good luck to all of you guys
coolfooldumbguy - October 17, 2025

KEZAR MAKES A SOLID COMEBACK!

$KZR   Kezar Life Sciences, Inc. (NASDAQ: KZR), a clinical-stage biotechnology company, reported positive top-line results...
AviseAnalytics - June 30, 2022

KZR - Monday Rundown, Tuesday Expectations

<< View Post To Watch Video >>
HDavis - November 15, 2021
View more Bullboard ››

Playboy Inc.

Playboy Inc.

Playboy, Inc. operates as a pleasure and leisure company in the United States, Australia, China, the United Kingdom, and ...
View More »

Podcasts